IMPORTANT EVENTS DURING THE THIRD QUARTER
Tasquinimod
- First patient dosed in the monotherapy part of the phase 1b/2a study in multiple myeloma
- The clinical study design for multiple myeloma will be presented at the virtual
American Society of Hematology meeting 2020 in December - Patents regarding treatment of acute leukemia granted in
Japan andChina
Laquinimod
- New ophthalmic formulation to be used in the treatment of inflammatory eye disorders developed
in collaboration withLeukocare AG
Naptumomab
- The clinical trial in combination with durvalumab in patients with advanced or metastatic solid cancer is ongoing
IMPORTANT EVENTS AFTER THE END OF THE PERIOD
Tasquinimod
- A notice of allowance has been issued for patent application regarding treatment of multiple myeloma in
China - Patent regarding use of tasquinimod in combination with immunotherapy granted in
Europe
Corporate
- The Board of directors decided on the Board meeting on
November 5, 2020 , to propose a rights issue to fund the ongoing and planned development programs - A Capital Markets Day will take place on
November 24, 2020
Financial summary
SEK M | Jul-Sep | Jan-Sep | Full-year | |||||
2020 | 2019 | 2020 | 2019 | 2019 | ||||
Net sales | – | 0.9 | 0.5 | 7.5 | 8.4 | |||
Operating loss | -8.3 | -9.3 | -28.2 | -21.1 | -32.3 | |||
Loss after tax | -8.2 | -9.3 | -28.2 | -22.9 | -34.1 | |||
Earnings per share (SEK) | -0.06 | -0.06 | -0.19 | -0.16 | -0.24 | |||
Cash and cash equivalents (at close of period) | 30.9 | 69.9 | 59.7 | |||||
For further information, please contact:
Helén Tuvesson, CEO Tel: +46 (0)46-19 21 56 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 | (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 (0)46-19 20 00 |
The report is also available at www.activebiotech.com.
Attachment
Active Biotech Interim report January –September 2020
© OMX, source